DHRS11 Knockout Raji Polyclonal Cells

The DHRS11 Knockout Raji Polyclonal Cells comprise a heterogeneous population of Raji B lymphocytes engineered via CRISPR/Cas9-mediated disruption of the DHRS11 gene. This polyclonal knockout pool provides a loss-of-function model to investigate the biological role of DHRS11, a short-chain dehydrogenase/reductase with oxidoreductase activity. The knockout strategy targets the coding region of DHRS11 to ablate functional protein expression across the cell population, enabling robust functional studies without clonal selection biases.

The Raji cell line, originally derived from a patient with EBV-positive Burkitt lymphoma, is a widely used lymphoblastoid model characterized by its B-cell origin and antigen-presenting capabilities. These cells express B-cell surface markers and major histocompatibility complex molecules, making them suitable for immunological and metabolic investigations. Their rapid proliferation and stable growth in suspension culture facilitate high-throughput assays, while their transformed phenotype offers insights into B-cell malignancies.

DHRS11 belongs to the short-chain dehydrogenase/reductase superfamily and catalyzes oxidation-reduction reactions dependent on NAD+/NADH cofactors. It is implicated in retinol metabolism, potentially participating in retinoid interconversion that influences cellular differentiation and redox homeostasis. Given its expression in B lymphocytes, DHRS11 may modulate metabolic pathways relevant to lymphoma biology. Functional studies using this knockout model are essential to clarify its role.

In Raji cells, which exhibit high metabolic activity due to continuous proliferation and EBV-driven transformation, DHRS11 may contribute to maintaining redox balance and sustaining energy metabolism. Disruption of DHRS11 in this lymphoblastoid background allows researchers to assess its role in B-cell-specific processes such as antigen presentation, cytokine production, and survival signaling. The polyclonal nature of the knockout population provides a robust average phenotype, reducing the risk of clone-specific artifacts and enhancing the reproducibility of functional assays.

These DHRS11 knockout Raji cells are ideally suited for a variety of downstream applications, including metabolic flux analysis, quantitative PCR and Western blotting to confirm gene disruption and assess compensatory pathways, and flow cytometric evaluation of B-cell activation markers. They enable investigation of DHRS11’s contribution to cancer metabolism within B-cell lymphomas and facilitate screening of compounds targeting retinoid-related pathways. For technical inquiries and product support, please contact Ascent Research.